5-HT1B/1D Agonist (Triptan)
Pregnancy: Avoid — limited data; sumatriptan has more safety data
Zolmitriptan
Brand names: Zomig
Adult dose
Dose: 2.5 mg oral at onset of migraine; may repeat after 2h if needed. Max 10 mg in 24h. Nasal spray: 5 mg per nostril; may repeat 5 mg after 2h.
Route: Oral or intranasal
Frequency: At migraine onset; may repeat after 2h
Max: 10 mg/24h
For acute migraine with or without aura. Not for prophylaxis. More lipid-soluble than sumatriptan — better CNS penetration. Nasal spray for rapid onset or when vomiting limits oral route.
Paediatric dose
Route: Oral or nasal
Frequency: Once; may repeat after 2h
Max: 5 mg per dose; 10 mg/24h
Concentration: Nasal spray 5 mg/actuation mg/ml
Adolescents ≥12 years: 2.5 mg oral or 5 mg nasal at migraine onset; max 5 mg per dose in adolescents. NICE: triptans licensed for adolescents ≥12 years.
Dose adjustments
Renal
No dose adjustment required
Hepatic
Reduce dose in moderate hepatic impairment — limit to 5 mg/24h
Clinical pearls
- Triptans are abortive, NOT prophylactic — explain mechanism to patients clearly
- Medication overuse headache (MOH): using triptans on ≥10 days/month can cause daily headache — regular review essential
- Nasal spray faster onset than oral — useful when early vomiting
- Cardiovascular risk check before prescribing triptans — screen for IHD, hypertension, and stroke history
Contraindications
- Ischaemic heart disease
- Coronary vasospasm
- Peripheral vascular disease
- Previous stroke or TIA
- Hemiplegic or basilar migraine
- Uncontrolled hypertension
- Ergotamine or ergot derivatives within 24h
- MAOIs within 14 days
Side effects
- Chest tightness/pressure (usually non-cardiac)
- Tingling/paraesthesia
- Dizziness
- Flushing
- Nausea
- Drowsiness
- Nasal irritation (nasal spray)
Interactions
- MAOIs — serotonin syndrome (avoid within 14 days)
- Ergotamine — additive vasospasm (separate by 24h)
- SSRIs/SNRIs — serotonin syndrome risk
- Cimetidine — doubles zolmitriptan levels (reduce dose to 5 mg max)
Monitoring
- Migraine frequency and severity diary
- Medication overuse (>10 days/month)
- Blood pressure
- Cardiovascular symptoms
Reference: BNFc; BNF; NICE NG150 Headaches; British Association for the Study of Headache (BASH) Guidelines. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Pathways
- Acute Stroke / TIA Assessment · NICE NG128; RCP Stroke Guidelines 2023
- Status Epilepticus (Adults) · NICE CG137; ESEM guidelines; RCP Neurology Guidelines
- Suspected Subarachnoid Haemorrhage · NICE NG228; RCEM 2023; AHA/ASA 2023
- Adult Head Injury · NICE NG232 (2023)
- Bell's Palsy / Facial Nerve Palsy · ENT UK 2017; AAN
- Vertigo Workup · ENT UK; NICE CKS